Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.

Kruis, W; Kiudelis, G; Rácz, I; A Gorelov, I; Pokrotnieks, J; Horynski, M; Batovsky, M; Kykal, J; Boehm, S; Greinwald, R; Mueller, R; Salofalk OD Study Group, International

doi:10.1136/gut.2008.154302

Public

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.

Shared by NobleBlocks on Feb 1, 2009 • 12:00 AM UTC

Authors:

W Kruis

G Kiudelis

I Rácz

Abstract

OBJECTIVES: To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis. DESIGN: A randomised, double-blind, double-dummy, parallel group, multicent...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!